Efficacy and safety of salvage radiotherapy for recurrent esophageal cancer after chemoradiotherapy: a Meta-analysis / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 892-897, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-910488
ABSTRACT
Objective:
To compare the efficacy and adverse events of salvage radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy in this Meta-analysis.Methods:
Databases including PubMed, Embase, Cochrane Library, CNKI and Wanfang data were searched from the inception to April 2020 to collect the clinical trials which comparatively analyzed the efficacy and safety between radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy. Meta-analysis was performed using RevMan 5.1 software. RR and 95% CI were used to describe the differences among different groups.Results:
According to the inclusion and exclusion criteria, a total of 11 clinical trials involving 842 patients were included. Meta-analysis showed that the overall survival in the salvage radiotherapy group was significantly lower than that in the salvage esophagectomy group ( RR=0.40, 95% CI 0.27-0.61, P<0.001), whereas significantly higher than that in the chemotherapy group ( RR=2.91, 95% CI 1.43-5.95, P=0.003). There was no significant difference in the treatment-related mortality between the salvage radiotherapy and salvage esophagectomy groups ( RR=0.53, 95% CI 0.14-1.98, P=0.350), but the incidence was significantly higher in the salvage esophagectomy group (1.7%-11.4% vs. 1.9%-2.8%).Conclusion:
Salvage radiotherapy is an effective treatment for recurrent esophageal cancer after chemoradiotherapy, which can be regarded as one choice for clinical patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Systematic reviews
Language:
Chinese
Journal:
Chinese Journal of Radiation Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS